Sweeney P, Park H, Baumann M, Dunlop J, Frydman J, Kopito R, et al. Protein misfolding in neurodegenerative diseases: implications and strategies. Transl Neurodegener. 2017;6:6.
Katsuno M, Sahashi K, Iguchi Y, Hashizume A. Preclinical progression of neurodegenerative diseases. Nagoya University Graduate School of Medicine, School of Medicine; 2018. https://doi.org/10.18999/nagjms.80.3.289. Cited 2023 Aug 1.
Metcalfe SM, Bickerton S, Fahmy T. Neurodegenerative disease: a perspective on cell-based therapy in the new era of cell-free nano-therapy. CPD. 2017;23:776–83.
Barthélemy NR, Salvadó G, Schindler SE, He Y, Janelidze S, Collij LE, et al. Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests. Nat Med. 2024;30:1085–95.
Gulisano W, Maugeri D, Baltrons MA, Fà M, Amato A, Palmeri A, et al. Role of amyloid-β and tau proteins in Alzheimer’s disease: confuting the amyloid cascade. Perry G, Avila J, Moreira PI, Sorensen AA, Tabaton M, editors. JAD. 2018;64:S611–31.
Abubakar MB, Sanusi KO, Ugusman A, Mohamed W, Kamal H, Ibrahim NH, et al. Alzheimer’s disease: an update and insights into pathophysiology. Front Aging Neurosci. 2022;14:742408.
Frisoni GB, Altomare D, Thal DR, Ribaldi F, Van Der Kant R, Ossenkoppele R, et al. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nat Rev Neurosci. 2022;23:53–66.
d’Errico P, Meyer-Luehmann M. Mechanisms of pathogenic tau and Aβ protein spreading in Alzheimer’s disease. Front Aging Neurosci. 2020;12:265.
Zhang H, Wei W, Zhao M, Ma L, Jiang X, Pei H, et al. Interaction between Aβ and tau in the pathogenesis of Alzheimer’s disease. Int J Biol Sci. 2021;17:2181–92.
Simon DK, Tanner CM, Brundin P. Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med. 2020;36:1–12.
DeMaagd G, Philip A. Parkinson’s disease and its management: part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. P T. 2015;40:504–32.
Ebrahimi-Fakhari D, Saidi L-J, Wahlster L. Molecular chaperones and protein folding as therapeutic targets in Parkinson’s disease and other synucleinopathies. Acta Neuropathol Commun. 2013;1:79.
Gómez-Benito M, Granado N, García-Sanz P, Michel A, Dumoulin M, Moratalla R. Modeling Parkinson’s disease with the alpha-synuclein protein. Front Pharmacol. 2020;11:356.
Paxinou E, Chen Q, Weisse M, Giasson BI, Norris EH, Rueter SM, et al. Induction of α-synuclein aggregation by intracellular nitrative insult. J Neurosci. 2001;21:8053–61.
Fields CR, Bengoa-Vergniory N, Wade-Martins R. Targeting alpha-synuclein as a therapy for Parkinson’s disease. Front Mol Neurosci. 2019;12:299.
McKeith I. Dementia with Lewy bodies. Dialogues Clin Neurosci. 2004;6:333–41.
Outeiro TF, Koss DJ, Erskine D, Walker L, Kurzawa-Akanbi M, Burn D, et al. Dementia with Lewy bodies: an update and outlook. Mol Neurodegener. 2019;14:5.
Haider A, Spurling BC, Sánchez-Manso JC. Lewy body dementia. In: StatPearls. Treasure Island: StatPearls Publishing; 2023. Available from: http://www.ncbi.nlm.nih.gov/books/NBK482441/. Cited 2024 Jan 5.
Kuhn J, Cascella M. Alexander disease. In: StatPearls. Treasure Island: StatPearls Publishing; 2023. Available from: http://www.ncbi.nlm.nih.gov/books/NBK562242/. Cited 2024 Jan 6.
Hagemann TL. Alexander disease: models, mechanisms, and medicine. Curr Opin Neurobiol. 2022;72:140–7.
Li W, Li J-Y. Overlaps and divergences between tauopathies and synucleinopathies: a duet of neurodegeneration. Transl Neurodegener. 2024;13:16.
Dugger BN, Dickson DW. Pathology of neurodegenerative diseases. Cold Spring Harb Perspect Biol. 2017;9:a028035.
Blokhuis AM, Groen EJN, Koppers M, Van Den Berg LH, Pasterkamp RJ. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125:777–94.
Hergesheimer RC, Chami AA, De Assis DR, Vourc’h P, Andres CR, Corcia P, et al. The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight? Brain. 2019;142:1176–94.
Ortiz GG, Ramírez-Jirano J, Arizaga RL, Delgado-Lara DLC, Torres-Sánchez ED. Frontotemporal-TDP and LATE neurocognitive disorders: a pathophysiological and genetic approach. Brain Sci. 2023;13:1474.
Bevan-Jones WR, Cope TE, Jones PS, Kaalund SS, Passamonti L, Allinson K, et al. Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum. Brain. 2020;143:1010–26.
Jiao H-S, Yuan P, Yu J-T. TMEM106B aggregation in neurodegenerative diseases: linking genetics to function. Mol Neurodegener. 2023;18:54.
Riku Y, Atsuta N, Yoshida M, Tatsumi S, Iwasaki Y, Mimuro M, et al. Differential motor neuron involvement in progressive muscular atrophy: a comparative study with amyotrophic lateral sclerosis. BMJ Open. 2014;4:e005213.
Cykowski MD, Powell SZ, Appel JW, Arumanayagam AS, Rivera AL, Appel SH. Phosphorylated TDP-43 (pTDP-43) aggregates in the axial skeletal muscle of patients with sporadic and familial amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2018;6:28.
De Boer EMJ, Orie VK, Williams T, Baker MR, De Oliveira HM, Polvikoski T, et al. TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J Neurol Neurosurg Psychiatry. 2021;92:86–95.
Bayazid R, Orru’ C, Aslam R, Cohen Y, Silva-Rohwer A, Lee S-K, et al. A novel subtype of sporadic Creutzfeldt-Jakob disease with PRNP codon 129MM genotype and PrP plaques. Acta Neuropathol. 2023;146:121–43.
Ferrer I, Puig B, Blanco R, Martı E. Prion protein deposition and abnormal synaptic protein expression in the cerebellum in Creutzfeldt-Jakob disease. Neuroscience. 2000;97:715–26.
Piccardo P, Ghetti B, Dickson DW, Vinters HV, Bugiani O, Tagliavini F, et al. Gerstmann-Sträussler-Scheinker Disease (PRNP P102L): amyloid deposits are best recognized by antibodies directed to epitopes in PrP region 90–165. J Neuropathol Exp Neurol. 1995;54:790–801.
Cracco L, Xiao X, Nemani SK, Lavrich J, Cali I, Ghetti B, et al. Gerstmann-Sträussler-Scheinker disease revisited: accumulation of covalently-linked multimers of internal prion protein fragments. Acta Neuropathol Commun. 2019;7:85.
Wan L, Zhu S, Chen Z, Qiu R, Tang B, Jiang H. Multidimensional biomarkers for multiple system atrophy: an update and future directions. Transl Neurodegener. 2023;12:38.
Ubhi K, Low P, Masliah E. Multiple system atrophy: a clinical and neuropathological perspective. Trends Neurosci. 2011;34:581–90.
Schweighauser M, Shi Y, Tarutani A, Kametani F, Murzin AG, Ghetti B, et al. Structures of α-synuclein filaments from multiple system atrophy. Nature. 2020;585:464–9.
Kovacs GG, Lukic MJ, Irwin DJ, Arzberger T, Respondek G, Lee EB, et al. Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol. 2020;140:99–119.
Martínez-Maldonado A, Ontiveros-Torres MÁ, Harrington CR, Montiel-Sosa JF, Prandiz RG-T, Bocanegra-López P, et al. Molecular processing of tau protein in progressive supranuclear palsy: neuronal and glial degeneration. Ávila J, editor. JAD. 2021;79:1517–31.
Darricau M, Katsinelos T, Raschella F, Milekovic T, Crochemore L, Li Q, et al. Tau seeds from patients induce progressive supranuclear palsy pathology and symptoms in primates. Brain. 2023;146:2524–34.
Van Eersel J, Bi M, Ke YD, Hodges JR, Xuereb JH, Gregory GC, et al. Phosphorylation of soluble tau differs in Pick’s disease and Alzheimer’s disease brains. J Neural Transm. 2009;116:1243–51.
Falcon B, Zhang W, Murzin AG, Murshudov G, Garringer HJ, Vidal R, et al. Structures of filaments from Pick’s disease reveal a novel tau protein fold. Nature. 2018;561:137–40.
Winklhofer KF, Tatzelt J, Haass C. The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J. 2008;27:336–49.
Balasco N, Diaferia C, Morelli G, Vitagliano L, Accardo A. Amyloid-like aggregation in diseases and biomaterials: osmosis of structural information. Front Bioeng Biotechnol. 2021;9:641372.
Lansbury PT. Yeast prions: inheritance by seeded protein polymerization? Curr Biol. 1997;7:R617–9.
Moreno-Gonzalez I, Soto C. Misfolded protein aggregates: mechanisms, structures and potential for disease transmission. Semin Cell Dev Biol. 2011;22:482–7.
Soto C, Pritzkow S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat Neurosci. 2018;21:1332–40.
Brundin P, Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol. 2010;11:301–7.
Lee S-J, Desplats P, Lee H-J, Spencer B, Masliah E. Cell-to-cell transmission of α-synuclein aggregates. In: Sigurdsson EM, Calero M, Gasset M, editors. Amyloid proteins. Totowa: Humana Press; 2012. p. 347–59. Available from: https://link.springer.com/10.1007/978-1-61779-551-0_23. Cited 2024 Jan 8.
Hijaz BA, Volpicelli-Daley LA. Initiation and propagation of α-synuclein aggregation in the nervous system. Mol Neurodegener. 2020;15:19.
Jucker M, Walker LC. Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat Neurosci. 2018;21:1341–9.
Li X, Ospitalieri S, Robberechts T, Hofmann L, Schmid C, Rijal Upadhaya A, et al. Seeding, maturation and propagation of amyloid β-peptide aggregates in Alzheimer’s disease. Brain. 2022;145:3558–70.
Goedert M, Spillantini MG. Propagation of Tau aggregates. Mol Brain. 2017;10:18.
Visanji NP, Brooks PL, Hazrati L-N, Lang AE. The prion hypothesis in Parkinson’s disease: Braak to the future. Acta Neuropathol Commun. 2013;1:2.
Steiner JA, Quansah E, Brundin P. The concept of alpha-synuclein as a prion-like protein: ten years after. Cell Tissue Res. 2018;373:161–73.
Rietdijk CD, Perez-Pardo P, Garssen J, Van Wezel RJA, Kraneveld AD. Exploring Braak’s hypothesis of Parkinson’s disease. Front Neurol. 2017;8. http://journal.frontiersin.org/article/10.3389/fneur.2017.00037/full. Cited 2024 Jul 23.
Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci. 2003;4:49–60.
Scannevin RH. Therapeutic strategies for targeting neurodegenerative protein misfolding disorders. Curr Opin Chem Biol. 2018;44:66–74.
Rao RV, Bredesen DE. Misfolded proteins, endoplasmic reticulum stress and neurodegeneration. Curr Opin Cell Biol. 2004;16:653–62.
Wang S, Kaufman RJ. The impact of the unfolded protein response on human disease. J Cell Biol. 2012;197:857–67.
Sammels E, Parys JB, Missiaen L, De Smedt H, Bultynck G. Intracellular Ca2+ storage in health and disease: a dynamic equilibrium. Cell Calcium. 2010;47:297–314.
Hwang J, Qi L. Quality control in the endoplasmic reticulum: crosstalk between ERAD and UPR pathways. Trends Biochem Sci. 2018;43:593–605.
Chen G, Wei T, Ju F, Li H. Protein quality control and aggregation in the endoplasmic reticulum: from basic to bedside. Front Cell Dev Biol. 2023;11:1156152.
Zhang SX, Sanders E, Fliesler SJ, Wang JJ. Endoplasmic reticulum stress and the unfolded protein responses in retinal degeneration. Exp Eye Res. 2014;125:30–40.
Wortel IMN, Van Der Meer LT, Kilberg MS, Van Leeuwen FN. Surviving stress: modulation of ATF4-mediated stress responses in normal and malignant cells. Trends Endocrinol Metab. 2017;28:794–806.
Xu M, Gelowani V, Eblimit A, Wang F, Young MP, Sawyer BL, et al. ATF6 is mutated in early onset photoreceptor degeneration with macular involvement. Invest Ophthalmol Vis Sci. 2015;56:3889.
Buchner J. Molecular chaperones and protein quality control: an introduction to the JBC Reviews thematic series. J Biol Chem. 2019;294:2074–5.
Kosmaoglou M, Schwarz N, Bett JS, Cheetham ME. Molecular chaperones and photoreceptor function. Prog Retin Eye Res. 2008;27:434–49.
Suss O, Reichmann D. Protein plasticity underlines activation and function of ATP-independent chaperones. Front Mol Biosci. 2015;2. Available from: http://journal.frontiersin.org/Article/10.3389/fmolb.2015.00043/abstract. Cited 2024 Jan 16.
Macošek J, Mas G, Hiller S. Redefining molecular chaperones as chaotropes. Front Mol Biosci. 2021;8:683132.
Saibil H. Chaperone machines for protein folding, unfolding and disaggregation. Nat Rev Mol Cell Biol. 2013;14:630–42.
Li J, Qian X, Sha B. Heat shock protein 40: structural studies and their functional implications. PPL. 2009;16:606–12.
Deane CAS, Brown IR. Components of a mammalian protein disaggregation/refolding machine are targeted to nuclear speckles following thermal stress in differentiated human neuronal cells. Cell Stress Chaperones. 2017;22:191–200.
Zhang L, Fok JHL, Davies FE. Heat shock proteins in multiple myeloma. Oncotarget. 2014;5:1132–48.
Wyszkowski H, Janta A, Sztangierska W, Obuchowski I, Chamera T, Kłosowska A, et al. Class-specific interactions between Sis1 J-domain protein and Hsp70 chaperone potentiate disaggregation of misfolded proteins. Proc Natl Acad Sci USA. 2021;118:e2108163118.
Wyżewski Z, Gregorczyk KP, Szulc-Dąbrowska L, Struzik J, Szczepanowska J, Niemiałtowski M. Cooperation between heat shock proteins in organizing of proteins spatial structure. Postepy Hig Med Dosw. 2014;68:793–807.
Ding J, Li J, Yang D, Yang F, Nie H, Huo Z, et al. Molecular characteristics of a novel HSP60 gene and its differential expression in Manila clams (Ruditapes philippinarum) under thermal and hypotonic stress. Cell Stress Chaperones. 2018;23:179–87.
Lopez T, Dalton K, Frydman J. The mechanism and function of group II chaperonins. J Mol Biol. 2015;427:2919–30.
Kim H, Park J, Roh S-H. The structural basis of eukaryotic chaperonin TRiC/CCT: action and folding. Mol Cells. 2024;47:100012.
Xu H. Cochaperones enable Hsp70 to use ATP energy to stabilize native proteins out of the folding equilibrium. Sci Rep. 2018;8:13213.
Fernández-Fernández MR, Valpuesta JM. Hsp70 chaperone: a master player in protein homeostasis. F1000Res. 2018;7:1497.
Sharma D, Masison D. Hsp70 structure, function, regulation and influence on yeast prions. PPL. 2009;16:571–81.
Peng S, Woodruff J, Pathak PK, Matts RL, Deng J. Crystal structure of the middle and C-terminal domains of Hsp90α labeled with a coumarin derivative reveals a potential allosteric binding site as a drug target. Acta Crystallogr D Struct Biol. 2022;78:571–85.
Amatya E, Blagg BSJ. Recent advances toward the development of Hsp90 C-terminal inhibitors. Bioorg Med Chem Lett. 2023;80:129111.
Serwetnyk MA, Blagg BSJ. The disruption of protein−protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition. Acta Pharm Sin B. 2021;11:1446–68.
Zuehlke A, Johnson JL. Hsp90 and co-chaperones twist the functions of diverse client proteins. Biopolymers. 2010;93:211–7.
Carrigan PE, Sikkink LA, Smith DF, Ramirez-Alvarado M. Domain:domain interactions within Hop, the Hsp70/Hsp90 organizing protein, are required for protein stability and structure. Protein Sci. 2006;15:522–32.
Di Donato M, Geisler M. HSP 90 and co-chaperones: a multitaskers’ view on plant hormone biology. FEBS Lett. 2019;593:1415–30.
Genest O, Wickner S, Doyle SM. Hsp90 and Hsp70 chaperones: collaborators in protein remodeling. J Biol Chem. 2019;294:2109–20.
Doyle SM, Hoskins JR, Kravats AN, Heffner AL, Garikapati S, Wickner S. Intermolecular interactions between Hsp90 and Hsp70. J Mol Biol. 2019;431:2729–46.
Bracher A, Verghese J. The nucleotide exchange factors of Hsp70 molecular chaperones. Front Mol Biosci. 2015;2. Available from: http://journal.frontiersin.org/article/10.3389/fmolb.2015.00010/abstract. Cited 2024 Jul 25.
Mogk A, Kummer E, Bukau B. Cooperation of Hsp70 and Hsp100 chaperone machines in protein disaggregation. Front Mol Biosci. 2015;2. Available from: http://www.frontiersin.org/Protein_Folding%2c_Misfolding_and_Degradation/10.3389/fmolb.2015.00022/abstract. Cited 2024 Jan 22.
Lee G, Kim RS, Lee SB, Lee S, Tsai FTF. Deciphering the mechanism and function of Hsp100 unfoldases from protein structure. Biochem Soc Trans. 2022;50:1725–36.
Tedesco B, Cristofani R, Ferrari V, Cozzi M, Rusmini P, Casarotto E, et al. Insights on human small heat shock proteins and their alterations in diseases. Front Mol Biosci. 2022;9:842149.
Carra S, Alberti S, Arrigo PA, Benesch JL, Benjamin IJ, Boelens W, et al. The growing world of small heat shock proteins: from structure to functions. Cell Stress Chaperones. 2017;22:601–11.
Yamamoto H, Matsui T. Molecular mechanisms of macroautophagy, microautophagy, and chaperone-mediated autophagy. J Nippon Med Sch. 2024;91:2–9.
Bejarano E, Cuervo AM. Chaperone-mediated autophagy. Proc Am Thorac Soc. 2010;7:29–39.
Kaushik S, Cuervo AM. Chaperone-mediated autophagy. In: Deretic V, editor. Autophagosome and phagosome. Totowa: Humana Press; 2008. p. 227–44. Available from: http://link.springer.com/10.1007/978-1-59745-157-4_15. Cited 2024 Jan 22.
Juste YR, Cuervo AM. Analysis of chaperone-mediated autophagy. In: Ktistakis N, Florey O, editors. Autophagy. New York: Springer New York; 2019. p. 703–27. Available from: http://link.springer.com/10.1007/978-1-4939-8873-0_47. Cited 2024 Jan 22.
Saha S, Buttari B, Profumo E, Tucci P, Saso L. A perspective on Nrf2 signaling pathway for neuroinflammation: a potential therapeutic target in Alzheimer’s and Parkinson’s diseases. Front Cell Neurosci. 2022;15:787258.
Pajares M, Cuadrado A, Rojo AI. Modulation of proteostasis by transcription factor NRF2 and impact in neurodegenerative diseases. Redox Biol. 2017;11:543–53.
Chen W-T, Dodson M. The untapped potential of targeting NRF2 in neurodegenerative disease. Front Aging. 2023;4:1270838.
Jiang T, Harder B, Rojo De La Vega M, Wong PK, Chapman E, Zhang DD. p62 links autophagy and Nrf2 signaling. Free Rad Biol Med. 2015;88:199–204.
Kageyama S, Saito T, Obata M, Koide R, Ichimura Y, Komatsu M. Negative regulation of the Keap1-Nrf2 pathway by a p62/Sqstm1 splicing variant. Mol Cell Biol. 2018;38:e00642–e717.
Mathur S, Gawas C, Ahmad IZ, Wani M, Tabassum H. Neurodegenerative disorders: assessing the impact of natural vs drug-induced treatment options. Aging Med. 2023;6:82–97.
Sivanandy P, Leey TC, Xiang TC, Ling TC, Wey Han SA, Semilan SLA, et al. Systematic review on Parkinson’s disease medications, emphasizing on three recently approved drugs to control Parkinson’s symptoms. IJERPH. 2021;19:364.
Murakami H, Shiraishi T, Umehara T, Omoto S, Iguchi Y. Recent advances in drug therapy for Parkinson’s disease. Intern Med. 2023;62:33–42.
AbbVie Launches PRODUODOPA® (foslevodopa/foscarbidopa) for people living with advanced Parkinson’s disease in the European Union open a printable version of this page email the URL of this page to a friend. 2024. Available from: https://news.abbvie.com/2024-01-09-AbbVie-Launches-PRODUODOPA-R-foslevodopa-foscarbidopa-for-People-Living-with-Advanced-Parkinsons-Disease-in-the-European-Union.
Rosebraugh M, Voight EA, Moussa EM, Jameel F, Lou X, Zhang GGZ, et al. Foslevodopa/foscarbidopa: a new subcutaneous treatment for Parkinson’s disease. Ann Neurol. 2021;90:52–61.
Henriksen T, Katzenschlager R, Bhidayasiri R, Staines H, Lockhart D, Lees A. Practical use of apomorphine infusion in Parkinson’s disease: lessons from the TOLEDO study and clinical experience. J Neural Transm. 2023;130:1475–84.
Van Wamelen DJ, Grigoriou S, Chaudhuri KR, Odin P. Continuous drug delivery aiming continuous dopaminergic stimulation in Parkinson’s disease. Brundin P, Langston JW, Bloem BR, editors. JPD. 2018;8:S65–72.
Espay AJ, Stocchi F, Pahwa R, Albanese A, Ellenbogen A, Ferreira JJ, et al. Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson’s disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial. Lancet Neurol. 2024;23:465–76.
Pagano G, Taylor KI, Anzures Cabrera J, Simuni T, Marek K, Postuma RB, et al. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease. Nat Med. 2024;30:1096–103.
Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer’s disease drug development pipeline: 2024. A&D Transl Res Clin Interv. 2024;10:e12465.
Belluck P. New drug approved for early Alzheimer’s. 2024.
Hey JA, Yu JY, Versavel M, Abushakra S, Kocis P, Power A, et al. Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of Alzheimer’s disease. Clin Pharmacokinet. 2018;57:315–33.
Tabuteau H, Jones A, Anderson A, Jacobson M, Iosifescu DV. Effect of AXS-05 (dextromethorphan-bupropion) in major depressive disorder: a randomized double-blind controlled trial. AJP. 2022;179:490–9.
Wang H-Y, Cecon E, Dam J, Pei Z, Jockers R, Burns LH. Simufilam reverses aberrant receptor interactions of filamin A in Alzheimer’s disease. IJMS. 2023;24:13927.
Khan SA, Khan S, Kausar H, Shah R, Luitel A, Gautam S, et al. Insights into the management of Lewy body dementia: a scoping review. Ann Med Surg. 2024;86:930–42.
Zilganersen sodium by Ionis Pharmaceuticals for Alexander disease: likelihood of approval. 2024. Available from: https://www.pharmaceutical-technology.com/data-insights/zilganersen-sodium-ionispharmaceuticals-alexander-disease-likelihood-of-approval/?cf-view.
Messing A, Daniels CML, Hagemann TL. Strategies for treatment in Alexander disease. Neurotherapeutics. 2010;7:507–15.
Liu Q, Zhu D, Jiang P, Tang X, Lang Q, Yu Q, et al. Resveratrol synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson disease in mice. Behav Brain Res. 2019;367:10–8.
Ahn S, Song T-J, Park S-U, Jeon S, Kim J, Oh J-Y, et al. Effects of a combination treatment of KD5040 and L-dopa in a mouse model of Parkinson’s disease. BMC Complement Altern Med. 2017;17:220.
Farkhondeh T, Folgado SL, Pourbagher-Shahri AM, Ashrafizadeh M, Samarghandian S. The therapeutic effect of resveratrol: focusing on the Nrf2 signaling pathway. Biomed Pharmacother. 2020;127:110234.
Griñán-Ferré C, Bellver-Sanchis A, Olivares-Martín M, Bañuelos-Hortigüela O, Pallàs M. Synergistic neuroprotective effects of a natural product mixture against AD hallmarks and cognitive decline in Caenorhabditis elegans and an SAMP8 mice model. Nutrients. 2021;13:2411.
Tsunekawa H, Noda Y, Mouri A, Yoneda F, Nabeshima T. Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25–35). Behav Brain Res. 2008;190:224–32.
Zhang C, Zang Y, Song Q, Li H, Hu L, Zhao W, et al. The efficacy of a “cocktail therapy” on Parkinson’s disease with dementia. NDT. 2019;15:1639–47.
Cummings JL, Osse AML, Kinney JW. Alzheimer’s disease: novel targets and investigational drugs for disease modification. Drugs. 2023;83:1387–408.
Melchiorri D, Merlo S, Micallef B, Borg J-J, Dráfi F. Alzheimer’s disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy? Front Pharmacol. 2023;14:1196413.
McFarthing K, Prakash N, Simuni T. Clinical trial highlights – dyskinesia. JPD. 2019;9:449–65.
Gaikwad S, Puangmalai N, Sonawane M, Montalbano M, Price R, Iyer MS, et al. Nasal tau immunotherapy clears intracellular tau pathology and improves cognitive functions in aged tauopathy mice. Sci Transl Med. 2024;16:eadj5958.
Add Comment